Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$135.80
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,924,443,648.00
EPSttm : 4.17
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$135.80
2.40%
$3.18

Float Short %

10.48

Margin Of Safety %

56

Put/Call OI Ratio

0.99

EPS Next Q Diff

0.21

EPS Last/This Y

2.76

EPS This/Next Y

5.08

Price

132.62

Target Price

205.2

Analyst Recom

1.18

Performance Q

-25.88

Relative Volume

0.69

Beta

0.66

Ticker: KRYS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07KRYS136.750.770.136904
2025-05-08KRYS137.170.570.266262
2025-05-09KRYS132.030.540.456355
2025-05-12KRYS139.440.491.917953
2025-05-13KRYS134.630.482.518199
2025-05-14KRYS131.340.770.039794
2025-05-15KRYS130.320.680.0810578
2025-05-16KRYS131.60.654.1011004
2025-05-19KRYS132.321.072.506546
2025-05-20KRYS131.611.050.006632
2025-05-21KRYS126.531.042.056665
2025-05-22KRYS125.251.090.036859
2025-05-23KRYS126.051.080.146884
2025-05-27KRYS127.450.870.088036
2025-05-28KRYS123.510.877.338064
2025-05-29KRYS125.520.880.758084
2025-05-30KRYS125.950.880.018083
2025-06-02KRYS125.350.791.338595
2025-06-03KRYS131.040.790.968624
2025-06-04KRYS132.120.805.358819
2025-06-05KRYS132.820.990.999863
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07KRYS136.80231.2104.47.65
2025-05-08KRYS137.2798.079.76.69
2025-05-09KRYS132.1835.269.65.88
2025-05-12KRYS139.4335.292.65.88
2025-05-13KRYS134.5335.270.05.88
2025-05-14KRYS131.4335.273.05.88
2025-05-15KRYS130.4135.276.95.88
2025-05-16KRYS130.5535.279.35.88
2025-05-19KRYS132.2935.282.15.88
2025-05-20KRYS131.5435.277.45.88
2025-05-21KRYS126.6335.269.45.88
2025-05-22KRYS125.2335.275.95.88
2025-05-23KRYS125.1135.278.45.88
2025-05-27KRYS126.4535.281.75.88
2025-05-28KRYS123.4435.272.85.88
2025-05-29KRYS125.4835.283.25.88
2025-05-30KRYS125.9635.279.55.88
2025-06-02KRYS125.2235.277.45.88
2025-06-03KRYS130.9135.290.15.88
2025-06-04KRYS132.1135.281.25.88
2025-06-05KRYS132.6235.279.95.88
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07KRYS-4.56-0.379.79
2025-05-08KRYS-4.56-0.379.79
2025-05-09KRYS-4.56-0.379.79
2025-05-12KRYS-4.56-2.149.58
2025-05-13KRYS-4.57-2.149.58
2025-05-14KRYS-4.57-2.149.58
2025-05-15KRYS-4.57-2.149.58
2025-05-16KRYS-4.57-2.149.58
2025-05-19KRYS-4.57-1.859.54
2025-05-20KRYS-4.68-1.859.54
2025-05-21KRYS-4.68-1.859.54
2025-05-22KRYS-4.68-1.859.54
2025-05-23KRYS-4.68-1.859.54
2025-05-27KRYS-4.68-2.059.54
2025-05-28KRYS-4.68-2.0510.48
2025-05-29KRYS-4.68-2.0510.48
2025-05-30KRYS-4.68-2.0510.48
2025-06-02KRYS-4.68-1.2710.48
2025-06-03KRYS-4.68-1.2710.48
2025-06-04KRYS-4.68-1.2710.48
2025-06-05KRYS-4.68-1.2710.48
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.26

Avg. EPS Est. Next Quarter

1.41

Insider Transactions

-4.68

Institutional Transactions

-1.27

Beta

0.66

Average Sales Estimate Current Quarter

95

Average Sales Estimate Next Quarter

105

Fair Value

206.74

Quality Score

87

Growth Score

44

Sentiment Score

79

Actual DrawDown %

39.5

Max Drawdown 5-Year %

-53.4

Target Price

205.2

P/E

31.94

Forward P/E

15.21

PEG

0.52

P/S

11.49

P/B

3.89

P/Free Cash Flow

29.64

EPS

4.15

Average EPS Est. Cur. Y​

5.88

EPS Next Y. (Est.)

10.95

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.18

Relative Volume

0.69

Return on Equity vs Sector %

-11.4

Return on Equity vs Industry %

6.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.7

EBIT Estimation

79.9
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading